The Peptide Field. Ipamorelin: approval and evidence record.

Editorial review: 2026-07-23. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/ipamorelin

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=ipamorelin#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Still being studied; no FDA-approved product identified

Exact product limits: Human studies used defined study material and routes. They do not establish the identity, safety, or equivalence of compounded mixtures or consumer-market products.

Human outcomes: Limited. A phase 2 trial did not show significant benefit on its key efficacy endpoint.

Body effects in people: Moderate. Dose-escalation work characterizes short-lived GH release in healthy volunteers.

What the evidence shows: The short hormone-response study was in healthy male volunteers. The phase 2 study was after bowel surgery. A dose-escalation study in healthy male volunteers characterized ipamorelin exposure and a short episode of GH release. In a multicenter, double-blind, placebo-controlled phase 2 trial after bowel surgery, the drug was described as well tolerated in that setting but did not significantly improve the key or secondary efficacy outcomes.

What remains unknown: Those studies do not establish popular claims about muscle gain, fat loss, recovery, anti-aging, or sleep. They also do not establish the safety or quality of consumer products, compounded combinations, or different routes.

Safety limits: FDA identifies immunogenicity, aggregation, impurity, and characterization concerns. The agency also cites serious adverse events, including death, in intravenous gastric-motility research and says it lacks sufficient information for other promoted injectable routes.

Sources used in the full review (a source is not support for every claim):

PubMed · Pharmaceutical Research. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. 1999. Accessed 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/10496658/

PubMed · International Journal of Colorectal Disease. Randomized proof-of-concept study of ipamorelin for postoperative ileus. 2015. Accessed 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/25331030/

U.S. Food and Drug Administration. Certain bulk drug substances that may present significant safety risks. 2026. Accessed 2026-07-23. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

World Anti-Doping Agency. 2026 prohibited list. 2026. Accessed 2026-07-23. https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list

Keep the limits, review date, and sources with this record. Check the current source for changes.